Under a tenth of individuals eligible to benefit from obesity jabs such as Wegovy are able to get them, states the global health agency as it issues its initial advice on the drugs.
Given more than one billion individuals worldwide currently classified as obese, it is urging increased and just availability to this class of drugs.
Per projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"Our new guidelines affirms that excess weight is a long-term condition that can be treated with holistic and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are significant hurdles to broad access to the jabs that can assist patients in reducing considerable body mass, notes the organization.
Skinny Jab Scarcity
Despite the current most optimistic scenario, the supply of these medications would only suffice for around 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The recommendation encourages nations and manufacturers to expand access, through measures like licensing agreements.
Exclusive production rights on a key compound – the main ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
How Obesity Jabs Work
GLP-1 drugs mimick a body's own hormone to delay gastric emptying, curb appetite and boost satiety so users consume fewer calories.
Patients usually begin shedding pounds within a few weeks of beginning the weekly injections.
Studies suggests people may put most of the weight back on after a year of halting the treatment, as their normal hunger return.
To be above a healthy weight elevates your likelihood for developing health problems, like diabetes, heart disease, brain attack, and some malignancies.
Excess weight affects people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.
